These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 9794564)

  • 21. Evaluation of red blood cell lipoperoxidation in hemodialysed patients during erythropoietin therapy supplemented or not with iron.
    Delmas-Beauvieux MC; Combe C; Peuchant E; Carbonneau MA; Dubourg L; de Précigout V; Aparicio M; Clerc M
    Nephron; 1995; 69(4):404-10. PubMed ID: 7777104
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Administration of exogenous erythropoietin beta affects lipid peroxidation and serum paraoxonase-1 activity and concentration in predialysis patients with chronic renal disease and anaemia.
    Marsillach J; Martínez-Vea A; Marcas L; Mackness B; Mackness M; Ferré N; Joven J; Camps J
    Clin Exp Pharmacol Physiol; 2007 Apr; 34(4):347-9. PubMed ID: 17324148
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical experience with Repotin, a locally produced recombinant human erythropoietin, in the treatment of anaemia of chronic renal failure in South Africa.
    Swanepoel CR; Moosa MR; Rowland GF; Meyers AM; Botha BP; Smart AJ; Goodman R; Schall R; Keogh HJ; Merrifield EH
    S Afr Med J; 1996 Oct; 86(10):1266-9. PubMed ID: 8955732
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recombinant human erythropoietin treatment of anemia in renal transplant patients.
    Lezaic V; Djukanovic L; Pavlovic-Kentera V
    Ren Fail; 1995 Nov; 17(6):705-14. PubMed ID: 8771243
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Orally administrated Juzen-taiho-to/TJ-48 ameliorates erythropoietin (rHuEPO)-resistant anemia in patients on hemodialysis.
    Nakamoto H; Mimura T; Honda N
    Hemodial Int; 2008 Oct; 12 Suppl 2():S9-S14. PubMed ID: 18837771
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Subcutaneous versus intravenous administration of erythropoietin improves its efficiency for the treatment of anaemia in haemodialysis patients.
    Albitar S; Meulders Q; Hammoud H; Soutif C; Bouvier P; Pollini J
    Nephrol Dial Transplant; 1995; 10 Suppl 6():40-3. PubMed ID: 8524493
    [TBL] [Abstract][Full Text] [Related]  

  • 27. How the duration period of erythropoietin treatment influences the oxidative status of hemodialysis patients.
    Dimitrijevic ZM; Cvetkovic TP; Djordjevic VM; Pavlovic DD; Stefanovic NZ; Stojanovic IR; Paunovic GJ; Velickovic-Radovanovic RM
    Int J Med Sci; 2012; 9(9):808-15. PubMed ID: 23136545
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reduced serum hydroxyl radical scavenging activity in erythropoietin therapy resistant renal anemia.
    Hirayama A; Nagase S; Gotoh M; Ueda A; Ishizu T; Yoh K; Aoyagi K; Terao J; Koyama A
    Free Radic Res; 2002 Nov; 36(11):1155-61. PubMed ID: 12592667
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Arterial hypertension in patients with chronic kidney insufficiency in hemodialysis with erythropoietin].
    Martins Prata M; Teixeira de Sousa F; Barbas J; Vinhaś J; Marques da Costa A
    Rev Port Cardiol; 1990 Feb; 9(2):119-23. PubMed ID: 2346662
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term effects on quality of life in haemodialysis patients of correction of anaemia with erythropoietin.
    Bárány P; Pettersson E; Konarski-Svensson JK
    Nephrol Dial Transplant; 1993; 8(5):426-32. PubMed ID: 8393547
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
    [TBL] [Abstract][Full Text] [Related]  

  • 32. UK Renal Registry 11th Annual Report (December 2008): Chapter 9 Haemoglobin, ferritin and erythropoietin amongst patients receiving dialysis in the UK in 2007: national and centre-specific analyses.
    Richardson D; Ford D; Gilg J; Williams AJ
    Nephron Clin Pract; 2009; 111 Suppl 1():c149-83. PubMed ID: 19542697
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of renal anaemia with erythropoiesis-stimulating agents in predialysis chronic kidney disease patients: Haemoglobin profile during the 6 months before initiation of dialysis.
    Kawahara K; Minakuchi J; Yokota N; Suekane H; Tsuchida K; Kawashima S
    Nephrology (Carlton); 2015 Dec; 20 Suppl 4():29-32. PubMed ID: 26456375
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Maintaining over time clinical performance targets on anaemia correction in unselected population on chronic dialysis at 20 Italian centres. Data from a retrospective study for a clinical audit.
    Soffritti S; Russo G; Cantelli S; Gilli G; Catizone L
    BMC Nephrol; 2009 Oct; 10():33. PubMed ID: 19852833
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Subcutaneous erythropoietin administration in predialysis patients: a single centre prospective study.
    Branger B; Vécina F; Zabadani B; Balducchi JP; Fourcade J
    Nephrol Dial Transplant; 1995; 10 Suppl 6():36-9. PubMed ID: 8524492
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Non-erythropoietin-based anaemia management in chronic kidney disease.
    Hörl WH
    Nephrol Dial Transplant; 2002; 17 Suppl 11():35-8. PubMed ID: 12386256
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Multicenter study of darbepoetin alfa in the treatment of anemia secondary to chronic renal insufficiency on dialysis].
    Martínez Castelao A; Reyes A; Valdés F; Otero A; López de Novales E; Pallardó L; Tabernero JM; Hernández Jaras J; Lladós F
    Nefrologia; 2003; 23(2):114-24. PubMed ID: 12778875
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Changes of endogenous erythropoietin level and iron status during a 30-month hemodialysis treatment of a group of patients.
    Majdan M; Ksiazek A; Bednarek-Skublewska A; Spasiewicz D
    Int Urol Nephrol; 2001; 33(3):541-6. PubMed ID: 12230292
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of oxidative stress and inflammation on rHuEPO requirements of hemodialysis patients with CRP values "in normal range".
    Tutal E; Sezer S; Bilgic A; Aldemir D; Turkoglu S; Demirel O; Ozdemir N; Haberal M
    Transplant Proc; 2007 Dec; 39(10):3035-40. PubMed ID: 18089316
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Homocysteine in chronic renal failure in relation to renal anemia and to oxidative stress parameters 4-hydroxynonenal and malondialdehyde.
    Carluccio F; Siems W; Stefanelli G; Sommerburg O; Grune T; Riedel E; Hampl H
    Clin Nephrol; 2002 Jul; 58 Suppl 1():S26-30. PubMed ID: 12227723
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.